Heterogeneity of monoclonal antibody distribution and radiation dose in tumors: a modeling analysis
- PMID: 1885162
Heterogeneity of monoclonal antibody distribution and radiation dose in tumors: a modeling analysis
Abstract
For successful use of monoclonal antibodies and their conjugates for diagnosis and therapy, it is helpful to understand both macroscopic and microscopic aspects of antibody distribution. Antibody distribution in a tumor is simulated by splicing together information on global pharmacokinetics, transport across the capillary wall, diffusive penetration through the tumor interstitial space, and antigen-antibody interaction. One interesting implication of this simulation is a microscopic dosimetry for radioimmunotherapy. The information of microscopic radioconjugate distribution will enable us to calculate absorbed dose in a tumor at the microscopic scale. The first step is to simulate the spatial antibody concentration profile in a tumor as a function of time after intravenous (bolus) injection, using reasonable values for the parameters involved. The second step is to calculate, also as a function of time, the absorbed radiation dose distribution resulting from each concentration profile. Parameter values for IgG pharmacology and a radiation point source function for I-131 are used to explore the effect of affinity on the antibody distribution and consequent absorbed dose in the tumor. The geometry simulated corresponds to a spherical nodule of densely packed tumor cells. Absorbed doses are calculated for radiation from a single nodule and for a cubic lattice of such nodules. This modeling analysis demonstrates that 1) antigen-antibody binding in tumors can retard antibody percolation; 2) high antibody affinity at a given dose tends to decrease antibody percolation and result in a heterogeneous distribution; 3) heterogeneous antibody distribution results in heterogeneous absorbed dose. This is more apparent in the case of radiation from a single nodule or small tumors. PERC and PERC-RAD, the computer program packages developed for these analyses, provide a convenient and flexible way to assess the impact of macroscopic and microscopic parameters on the distribution of immunoconjugates (PERC) and the consequent absorbed radiation dose in tumors (PERC-RAD). This mathematical model and the general principles developed here can be applied as well as to other biological ligands and beta-emitters.
Similar articles
-
Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution.Cancer Res. 1991 Sep 15;51(18):4821-7. Cancer Res. 1991. PMID: 1893374
-
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.J Nucl Med. 1990 Jul;31(7):1191-8. J Nucl Med. 1990. PMID: 2362198
-
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.Cancer Res. 1989 Oct 15;49(20):5656-63. Cancer Res. 1989. PMID: 2790783
-
Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier".Cancer Res. 1992 May 1;52(9 Suppl):2747s-2751s. Cancer Res. 1992. PMID: 1563006 Review.
-
The macroscopic and microscopic pharmacology of monoclonal antibodies.Int J Immunopharmacol. 1992 Apr;14(3):457-63. doi: 10.1016/0192-0561(92)90176-l. Int J Immunopharmacol. 1992. PMID: 1618598 Review.